# Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

> **NCT06803693** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 152 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab vedotin
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Zanubrutinib
- **DRUG:** Lenalidomide
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT06803693
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06803693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06803693, "Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06803693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*